COMPANY:

OncoAssure

"New data presented at AUA 2026 in Washington, DC (Abstract IP31-22) show that OncoAssure Prostate, a six-gene Molecular Clinical Risk Score (MCRS), outperforms standard NCCN and CAPRA risk models in men with clinically low-risk prostate cancer. In a study of 233 patients from Irish and Swedish cohorts, the MCRS was significantly more prognostic for adverse pathology, high primary Gleason grade, and biochemical recurrence, and added value when combined with clinical assessment. Decision curve analysis confirmed greater net clinical benefit, supporting OncoAssure Prostate as a tool to better identify candidates for active surveillance versus treatment."

"OncoAssure Ltd...is proud to announce an exclusive partnership with Illinois-based GoPath Diagnostics. Under this agreement, GoPath, a leading full-service CAP-accredited and CLIA-certified anatomic, molecular, and digital pathology company, will hold the exclusive rights to provide the OncoAssure™ Prostate test throughout the United States."

"DiaCarta...today announced that it has established a strategic collaboration with OncoAssure...The focus of the collaboration is to commercialize OncoAssure’s groundbreaking Prostate test which is designed to identify patients with a lower risk of prostate cancer recurrence, guiding decisions on active surveillance or reduced monitoring post-treatment."